Search      Advanced Search | Browse By Topic
Magazine Content
Home
Features
Columnists
Industry Risk Reports
In-Depth Series
Special Reports
Point/Counterpoint
R&I One® Content
News & Analysis
Editor's Choice Stories
Resources and Tools
Power Broker® Directory
Risk InnovatorTM
Emerging Risks
Top Employee Benefits Consultant
Executives To Watch
Insights
Industry Events
WorkersComp Forum
Award Nominations
Webinars
RSS
R&I Information
Subscription Center
Advertiser Information
About Us
Contact Us
 

Newsletter Sign-up

Click on the name of the free newsletter below to preview:

R&I One®
WORKERSCOMP Forum TM Update
HTML Text
E-Mail Address:


Click here to unsubscribe
Privacy Policy
Preferences

 

Ohio: Bureau working on outpatient medication formulary

The Bureau of Workers' Compensation proposed changes to a rule adopting an outpatient medication formulary indicated in an appendix.

Print Email Add to Facebook Add to Twitter Add to LinkedIn Write to the Editor Reprints

The formulary in the appendix will constitute the complete list of medications that are approved for reimbursement by the bureau for treatment of a work-related injury or disease in an allowed claim. Drugs not listed in the formulary are not eligible for reimbursement by the bureau. The formulary indicated in the appendix also contains specific reimbursement, prescribing or dispensing restrictions that have been placed on the use of listed drugs. The formulary will be reviewed annually and updated as necessary. The most current version will be electronically published by the bureau. The bureau's pharmacy and therapeutics committee will evaluate and make recommendations to the administrator regarding the addition, deletion or modification of coverage of medications listed in the formulary.

Requests for pharmacy and therapeutics committee action on a specific drug may be initiated by the bureau's administrator, chief of medical services, chief medical officer, or pharmacy director. According to the rule, the bureau will develop policies to perform an expedited review process for clinically or therapeutically unique medications. The bureau will also develop policies to address the timely review of new drug products. The rule is effective Sept. 1.

Read more at the WorkersComp Forum homepage.

May 26, 2011

Copyright 2011© LRP Publications

 
 
 
 
 
 
 
 
 
 
 
RISK logo
 

Back to top

Entire contents copyright © 2013 Risk and Insurance® All rights reserved. May not be reproduced in any form without written permission.